Skip to main content
Clinical Trials/NCT01106365
NCT01106365CompletedNot Applicable

Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis - A Pilot Study to Evaluate Safety and Efficacy of Deep rTMS on Fatigue and Depressivity in Patients With Multiple Sclerosis

Charite University, Berlin, Germany1 site in 1 country36 target enrollmentStarted: February 1, 2010Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
36
Locations
1
Primary Endpoint
Safety

Study Overview

Brief Summary

Multiple sclerosis (MS) is a chronic-inflammatory autoimmune central nervous system disorder and a leading cause of neurological disability in younger adults in Western countries. Besides "classic" neurological symptoms both depressivity and fatigue are among the most frequent symptoms in MS, affecting up to 90% of patients at onset or during the course of the disease. Neither are the psychological and immunological backgrounds of both well understood, nor are there numerous controlled therapeutic trials which would offer convincing treatment options for fatigue and depressivity in MS.

Transcranial magnetic stimulation (TMS) has been frequently used to investigate altered hemispheric and inter-hemispheric connectivity in MS. Recently, first therapeutic trials have been performed to address specific MS-related symptoms by TMS. Koch et al. demonstrated an improvement of hand dexterity following repetitive TMS, and Centonze and colleagues showed reduced spasticity following TMS.

Recently, a specific coil for the stimulation of deeper brain regions including the deep nuclei was developed, the so-called H-coil. It successfully stimulates deeper (pre-frontal) brain regions. Stimulation with this coil has been shown to be safe and well tolerated in healthy volunteers, and in patients suffering from major depression.

The aim of this project is to apply deep TMS with the H-coil to the prefrontal cortex (PFC) of MS patients. The PFC is the region at which stimulation is aimed in previous depression studies as this brain region has been shown to play a relevant role in affective disorders. It is the primary aim of this study, to evaluate the safety and tolerability of deep TMS with the H-coil in MS patients with fatigue or depressivity.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Male and female patients with clinically definite MS according to Polman
  • •Age 18 to 60
  • •EDSS 0 to 6
  • •Relapse-free > 30 days prior to inclusion
  • •Stable immunomodulatory or immunosuppressive therapy or treatment-naïve for > 3 months prior to inclusion
  • •In case of treatment with antidepressants: stable therapy > 3 months
  • •A score of ≥ 4 on the FSS (fatigue severity scale)8 or
  • •A score of ≥ 12 on the Beck Depression Inventory (BDI)
  • •Highly effective methods of birth control for females

Exclusion Criteria

  • •Personal or family history of epilepsy, brain tumor, brain injury
  • •History of metallic particles in the eye or head outside the mouth
  • •Cardiac pacemakers, implanted neurostimulators, cochlear implants, implanted medication pumps
  • •History of drug or alcohol abuse
  • •Pregnancy
  • •Relapse of MS < 30 days prior to inclusion
  • •I.v. corticosteroid treatment < 30 days prior to inclusion
  • •Change of immunomodulatory therapy < 30 days prior to inclusion
  • •Change of antidepressant therapy < 3 months prior to inclusion
  • •Comedication with neuroleptics and tricyclic antidepressants (amitriptyline etc.) during the entire study
  • •patients with increased intracranial pressure (which lowers seizure threshold)
  • •intracardiac lines
  • •significant heart disease
  • •bipolar disorder
  • •history of stroke or other brain lesions

Arms & Interventions

prefrontal cortex (PFC)

Experimental

rTMS with the H-coil to the prefrontal cortex (PFC)

Intervention: H-coil (Repetitive deep transcranial magnetic stimulation) (Device)

motor cortex

Active Comparator

rTMS with the H-coil to the motor cortex

Intervention: H-coil (Repetitive deep transcranial magnetic stimulation) (Device)

sham treatment

Sham Comparator

sham treatment

Intervention: H-coil (Repetitive deep transcranial magnetic stimulation) (Device)

Outcomes

Primary Outcomes

Safety

Time Frame: 3x/week during treatment phase

examination by physician, assessement of adverse events

Secondary Outcomes

  • Fatigue(3x/week during treatment period)
  • Depressivity(3x/week during treatment period)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Friedemann Paul

MD

Charite University, Berlin, Germany

Study Sites (1)

Loading locations...

Similar Trials